Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
89,563,791
-
Share change
-
+2,494,590
-
Total reported value
-
$6,415,135,392
-
Put/Call ratio
-
43%
-
Price per share
-
$71.62
-
Number of holders
-
328
-
Value change
-
+$224,593,251
-
Number of buys
-
164
-
Number of sells
-
140
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2023
As of 31 Dec 2023,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
328 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
89,563,791 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Inc., WASATCH ADVISORS LP, Bellevue Group AG, Avoro Capital Advisors LLC, STATE STREET CORP, JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, and Deep Track Capital, LP.
This page lists
328
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.